SWOG clinical trial number
SWOG-8593 (INT-0065)

A Randomized Trial of Prophylactic Isolation Perfusion for Stage I High Risk Malignant Melanoma of the Limbs

Closed
Phase
Published
Abbreviated Title
A Randomized Trial of Prophylactic Isolation Perfusion for Stage I High Risk Malignant Melanoma of the Limbs
Activated
10/01/1986
Closed
07/01/1991

Research committees

Melanoma

Publication Information Expand/Collapse

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

1998

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial.

H Koops;M Vaglini;S Suciu;BBR Kroon;JF Thompson;J Gohl;AMM Eggermont;F Di Filippo;ET Krementz;D Ruiter;FJ Lejeune Journal of Clinical Oncology 16(9):2906-2912

1997

Treatment of in-transit melanoma metastases with tumour necrosis factor (TNF-a) and chemotherapy administered in isolated limb perfusion (ILP).

F Lejeune;D Lienard;H Schraffordt Koops;B Kroon;A Eggermont 4th World Conference on Melanoma- Sydney Australia 7(Suppl.1):848(#167)

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase